Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies

研究总结 在美国，酒精使用障碍(AUDS)的患病率约为12.7%，并显示出明显的 近年来有所增加(Grant等人，2017年)。患有AUD的人经常使用大麻，这可能会影响 试图减少或戒酒。在过去的六年里，美国见证了巨大的变化 关于公众对大麻的接受和可获得性。考虑到历史上大麻一直是 AUD患者最常使用的药物，考虑到AUD可获得性的飙升 对于大麻产品，卫生保健提供者必须了解如何最好地使用大麻 那些患有澳门氏症并想要接受治疗的人。拟议研究的中心前提是 低THC和高CBD的产品对想要戒酒的澳大利亚人的伤害可能较小，因为 与仅含高THC的产品相比。根据假设，从高THC产品转换的个人 较低的THC和较高的CBD产品将显示出比那些 请不要切换。如果这些假设得到支持，这项研究的传播将立即产生 通过教育患者和治疗提供者如何解决使用 想要戒烟或减少酒精消费的人中有大麻。为此，那些 目前使用高THC产品并想要减少或戒酒将被随机分配到 控制条件(如您所愿继续使用您当前的大麻产品)或干预条件 (切换到低THC/高CBD产品的说明)。在干预条件下的参与者选择 在研究期间生产和使用他们想要的少或多。参与者将在Mobile中接受测试 药理实验室在6周和12周的时间点上确定这些产品对CUE诱导的影响 焦虑，暗示引发的酒精渴望，饮酒结果，以及全身炎症的生物标志。

Research Summary The prevalence of alcohol use disorders (AUDs) in the U.S. is approximately 12.7% and has shown a marked increase in recent years (Grant et al., 2017). Individuals with AUD often use cannabis, which may impact attempts to reduce or quit drinking. In the last six years, the United States has witnessed enormous changes concerning the public acceptance and availability of cannabis. Considering that cannabis has historically been the drug most often used by individuals with an AUD and considering the skyrocketing increase in availability of cannabis products, it is imperative for health care providers to understand how best to approach cannabis use with individuals who have an AUD and who want treatment. The central premise of the proposed research is that products with low THC and high CBD may be less harmful to AUD individuals who want to quit drinking, as compared to products with high THC only. It is hypothesized that individuals who switch from a high THC product to a low THC and higher CBD product will demonstrate superior outcomes compared to those individuals who do not switch. If the hypotheses are supported, the dissemination of the research would have an immediate effect on public health impact by educating patients and treatment providers about how to address the use of cannabis among individuals who want to quit or reduce alcohol consumption. To that end, individuals who currently use a high THC product and want to reduce or quit drinking will be randomly assigned to either the control condition (continue to use your current cannabis product as you wish) or the intervention condition (instruction to switch to low THC/high CBD product). Participants in the intervention condition choose the product and use as little or as much as they want during the study. Participants will be tested in the Mobile Pharmacology Laboratory at 6 and 12 week timepoints to determine the impact of these products on cue-elicited anxiety, cue-elicited alcohol craving, drinking outcomes, and biological markers of systemic inflammation.